Journal ArticleDOI
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
Victor W. Nitti,Roger R. Dmochowski,Sender Herschorn,Peter K. Sand,Catherine Thompson,Christopher Nardo,Xiaohong Yan,Cornelia Haag-Molkenteller +7 more
Reads0
Chats0
TLDR
OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated.About:
This article is published in The Journal of Urology.The article was published on 2013-06-01. It has received 286 citations till now. The article focuses on the topics: Overactive bladder & Urinary incontinence.read more
Citations
More filters
Journal ArticleDOI
OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
Christopher R. Chapple,Karl-Dietrich Sievert,Scott MacDiarmid,Vik Khullar,Piotr Radziszewski,Christopher Nardo,Catherine Thompson,J. Zhou,Cornelia Haag-Molkenteller +8 more
TL;DR: OnabotulinumtoxinA 100 U was well tolerated and demonstrated significant and clinically relevant improvements in all OAB symptoms, patient-reported benefit, and HRQOL in patients inadequately managed by anticholinergics.
Journal ArticleDOI
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Altaf Mangera,Apostolos Apostolidis,Karl Eric Andersson,Prokar Dasgupta,Antonella Giannantoni,Claus G. Roehrborn,Giacomo Novara,Christopher R. Chapple +7 more
TL;DR: BoNTA significantly improves all symptoms and urodynamic parameters in NDO and OAB, and the effect of BoNTA in treating LUTS dysfunction appears to be overestimated in lower as opposed to higher LE studies.
Journal ArticleDOI
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients With an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
Marcus J. Drake,Christopher R. Chapple,Ahmet Adil Esen,Stavros Athanasiou,Javier Cambronero,David Mitcheson,Sender Herschorn,Tahir Saleem,Moses Huang,Emad Siddiqui,Matthias Stölzel,Claire Herholdt,Scott MacDiarmid +12 more
TL;DR: Adding mirabegron 50mg to solifenacin 5mg further improved OAB symptoms versus solifein 5 or 10mg, and it was well tolerated in OAB patients remaining incontinent in this 12-wk study.
Journal ArticleDOI
Botulinum toxin: State of the art
TL;DR: The use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions.
References
More filters
Journal ArticleDOI
Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study
Debra E. Irwin,Ian Milsom,Steinar Hunskaar,Kate Reilly,Zoe Kopp,Sender Herschorn,Karin S. Coyne,Con Kelleher,Christian Hampel,Walter Artibani,Paul Abrams +10 more
TL;DR: The EPIC study is the largest population-based survey to assess prevalence rates of OAB, UI, and other LUTS in five countries and is the first study to evaluate these symptoms simultaneously using the 2002 ICS definitions.
Journal ArticleDOI
Prevalence and burden of overactive bladder in the United States
Walter F. Stewart,J B Van Rooyen,Geoffrey W. Cundiff,Paul Abrams,A R Herzog,R Corey,Timothy L. Hunt,Alan J. Wein +7 more
TL;DR: The NOBLE studies do not support the commonly held notion that women are considerably more likely than men to have urgency-related bladder control problems, and overactive bladder, with and without urge incontinence, has a clinically significant impact on quality-of-life, quality- of-sleep, and mental health, in both men and women.
Journal ArticleDOI
An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction
Bernard T. Haylen,Dirk De Ridder,Robert Freeman,Steven Swift,Bary Berghmans,Joseph C. Lee,Ash Monga,Eckhard Petri,Diaa E. E. Rizk,Peter K. Sand,Gabriel N. Schaer +10 more
TL;DR: A consensus-based terminology report for female pelvic floor dysfunction has been produced aimed at being a significant aid to clinical practice and a stimulus for research.
Journal ArticleDOI
How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.
TL;DR: The prevalence of chronic and debilitating symptoms of the overactive bladder are determined as the presence of chronic frequency, urgency and urge incontinence (either alone or in any combination), and presumed to be caused by involuntary detrusor contractions.